Menu
Four drugmakers announced 340B refunds, while another said it will discontinue certain formulations of a cancer drug in recent notices to 340B covered entities.

Four Drugmakers Announce 340B Refunds, One Discontinues Drug

Luke Zarzecki, National Correspondent 340B Report Views
Four drugmakers recently announced refunds to covered entities that purchased certain 340B drugs between 2023 and 2026, while another disclosed [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

SpendMend 340B Solution–340B Unscripted Podcast

More 340B Stakeholders Line Up White House Meetings on Rebate Model

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Site Footer Live